Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It works the same way as CJC-1295 and sermorelin - prompting the pituitary to release growth hormone - but it is the one member of that family that completed development and reached approval.

What is tesamorelin approved for?

Reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. That is a specific complication in a specific patient group, and it is what the trials measured.

Does tesamorelin work for body composition in healthy adults?

Nobody has tested that. The trials are in people with HIV-associated lipodystrophy, where visceral fat accumulation is a recognised clinical problem. Reading across from that population to a healthy adult wanting to lose belly fat is an extrapolation the evidence does not license.

How does tesamorelin compare to CJC-1295 or sermorelin?

Same mechanism class, very different evidence. Tesamorelin has 26 randomised trials and an approval; CJC-1295 has no completed development programme; sermorelin was approved for paediatric growth hormone deficiency and later discontinued. If you are comparing GHRH analogues, this is the one where the science finished.

Is tesamorelin sold as a research chemical?

It appears in the same grey channels as the research GH peptides, which is the problem. An approved, quality-controlled version exists and requires a prescriber; a vial bought online carries the name without any of that.

Prescription / GLP-1

Tesamorelin: The GHRH Peptide That Actually Cleared Approval

Same class as CJC-1295 and sermorelin, but with 26 randomised trials and an FDA approval - for visceral fat in people with HIV. That specificity is the point.

Written bySebastian Hunter, Founder and Editor

Published August 23, 2026

Start here

Plain English

Tesamorelin is a growth-hormone-releasing hormone analogue, the same class as CJC-1295 and sermorelin. Unlike them it has 26 randomised trials and an FDA approval - for reducing excess visceral fat in people with HIV-associated lipodystrophy. It is the best evidence this class has, and it is narrower than the marketing around the class implies.

26 randomised trials, including one in JAMA.
Approved for a specific population, with visceral fat as the endpoint.
It is the class working - in patients with a diagnosed condition.

If you have read our pages on CJC-1295, ipamorelin or sermorelin, you have seen the same shape repeatedly: a growth-hormone-releasing peptide with a plausible mechanism and thin human evidence for what it is sold to do.

Tesamorelin is the one that finished. Same class, same mechanism, 26 randomised controlled trials, and an FDA approval. It is the best evidence this entire family has — which makes what the trials actually showed unusually worth knowing.

What it was approved for

Reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy — a condition in which fat redistributes in ways that are metabolically harmful and difficult to treat.

That is not a footnote to the approval. It is the approval.

Tesamorelin randomised trials cited here, by population

People with HIV-associated fat changesincluding a JAMA trial
4
Healthy adults, body compositionthe reason people look it up
0

Every trial is in people with HIV. The evidence that makes tesamorelin the credible member of the GHRH family is evidence about a specific clinical complication, not about body composition in general.

The programme ran from early trials of the growth hormone-releasing factor in HIV Falutz 2010 - Falutz J, Potvin D, Mamputu JC et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. (opens PubMed in a new tab), through a randomised trial in JAMA measuring effects on visceral fat and liver fat Stanley 2014 - Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. (opens PubMed in a new tab), safety and metabolic work Clemmons 2017 - Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. (opens PubMed in a new tab), and on to more recent evaluation in people taking integrase inhibitors Russo 2024 - Russo SC, Ockene MW, Arpante AK et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. (opens PubMed in a new tab).

Why this page matters if you are looking at the other GH peptides

The argument for CJC-1295, ipamorelin, sermorelin and the rest usually runs: this class raises growth hormone, growth hormone affects body composition, therefore.

Tesamorelin is where that argument was actually tested to a conclusion. And the conclusion that cleared approval was narrow: a specific fat compartment, in a specific patient group, with a specific clinical problem.

Dose and supply

Tesamorelin has an approved product with a label, a prescriber, and manufacturing to pharmaceutical standards. Its dosing is a clinical decision made in the context of a diagnosis.

It also turns up in the same research-chemical channels as the unapproved GH peptides, sold to people who do not have the condition it was approved for. That combination — an approved medicine sold as a research chemical for an unapproved use — is the worst of both arrangements: you take on the risks of the grey market to obtain something that exists in a controlled form.

Status

US legal status - FDA-approved · prescription only

Tesamorelin is an FDA-approved prescription medicine for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. It requires a prescriber. Grey-market vials carry the name without the approval, the quality control, or the indication.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.